State Medicaid programs have considered a single preferred drug list (PDL) for multiple reasons, such as providing smooth continuity of care transitions for members who move between managed care plans, reducing confusion and potential administrative complexities for physicians who currently have Medicaid patients subject to different PDLs, and the potential to maximize federal and supplemental drug rebate dollars paid to the state. This paper discusses several decision points and considerations for states evaluating a single PDL requirement.